Back to All Combinations

Lynch Syndrome

Good Prognosis
3.00% Prevalence Level 1 Special Populations
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
MLH1 MSH2 MSH6 PMS2 EPCAM
Treatment Implications

Hereditary. MSI-H tumors respond to immunotherapy. Family screening essential.

Recommended Treatments
Immunotherapy
Surveillance
Family counseling
Treatments to Avoid

No specific contraindications noted

Study References

NCCN Genetic

Key Statistics
3.00%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Screen all CRC <50 and all MSI-H.
Information

Category: Special Populations

Evidence Level: Level 1

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.